Issued December 2013 AN: 01018/2012 SUMMARY OF PRODUCT
... the bitch at the same time as the puppies. Not for use in dogs weighing less than 2.5 kg. For routine worm control adult dogs should be treated every 3 months. For routine treatment a single dose is recommended. In the event of heavy roundworm infestation a repeat dose should be given after 14 days. ...
... the bitch at the same time as the puppies. Not for use in dogs weighing less than 2.5 kg. For routine worm control adult dogs should be treated every 3 months. For routine treatment a single dose is recommended. In the event of heavy roundworm infestation a repeat dose should be given after 14 days. ...
Chapter 6 - Diabetes and Endocrinology
... When glycaemic control is inadequate with existing treatment sitagliptin (DPP-4 inhibitor) can be added to metformin or a sulphonylurea or both if insulin is unacceptable. Treatment should only be continued if HbA1c is reduced by at least 0.5% within 6 months of starting treatment. Evidence suggests ...
... When glycaemic control is inadequate with existing treatment sitagliptin (DPP-4 inhibitor) can be added to metformin or a sulphonylurea or both if insulin is unacceptable. Treatment should only be continued if HbA1c is reduced by at least 0.5% within 6 months of starting treatment. Evidence suggests ...
Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the
... cyclophosphamide via conversion to dechloroethylcyclophosphamide (35). The importance of the CYP enzymes in anticancer pharmacokinetics has been well described (36, 37), and ethnic differences in the activity of several CYP enzymes are known (38, 39). One salient study of breast cancer patients show ...
... cyclophosphamide via conversion to dechloroethylcyclophosphamide (35). The importance of the CYP enzymes in anticancer pharmacokinetics has been well described (36, 37), and ethnic differences in the activity of several CYP enzymes are known (38, 39). One salient study of breast cancer patients show ...
Basic Principles of GMP - World Health Organization
... pharmacoepidemiological studies to be performed (more details in the EMEA guideline on Conduct of Pharmacovigilance for Medicines used by the Paediatric Population, 28 June 2006). However, this all concerns ONLY new medicines ...
... pharmacoepidemiological studies to be performed (more details in the EMEA guideline on Conduct of Pharmacovigilance for Medicines used by the Paediatric Population, 28 June 2006). However, this all concerns ONLY new medicines ...
The enzyme as drug: application of enzymes as pharmaceuticals
... enzymes used as anticoagulant or coagulant agents have since been approved by the FDA. In 1990, Adagen1, a form of bovine adenosine deaminase (ADA) treated with polyethylene glycol (PEG) was approved to treat patients afflicted with a type of severe combined immunodeficiency disease (SCID), which is ...
... enzymes used as anticoagulant or coagulant agents have since been approved by the FDA. In 1990, Adagen1, a form of bovine adenosine deaminase (ADA) treated with polyethylene glycol (PEG) was approved to treat patients afflicted with a type of severe combined immunodeficiency disease (SCID), which is ...
... The information presented herein reflects the opinions of the contributors and advisors. It should not be interpreted as an official policy of ASHP or as an endorsement of any product. Because of ongoing research and improvements in technology, the information and its applications contained in this ...
Product Monograph - Ask Novartis Pharma
... Animal Data: No teratogenic effects were observed when valsartan was administered orally to pregnant mice and rats at doses up to 600 mg/kg/day and to pregnant rabbits at oral doses up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rate and slight del ...
... Animal Data: No teratogenic effects were observed when valsartan was administered orally to pregnant mice and rats at doses up to 600 mg/kg/day and to pregnant rabbits at oral doses up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rate and slight del ...
Analgesic Activities of Methanol Extract of Terminalia chebula Fruit
... Pain is a sensation which in many cases represents the only symptom for the diagnosis of several disorders. Throughout ages man has used many different remedies for pain relief, among which medicinal herbs are most common due to their efficacy and relative safety due to their natural origin. In pres ...
... Pain is a sensation which in many cases represents the only symptom for the diagnosis of several disorders. Throughout ages man has used many different remedies for pain relief, among which medicinal herbs are most common due to their efficacy and relative safety due to their natural origin. In pres ...
How do you switch between tricyclic, SSRI and related
... Agomelatine is an antidepressant agent with selective agonist action at melatonin receptors and selective antagonist action at serotonin 5HT-2C receptors. It does not affect uptake of serotonin, noradrenaline or dopamine [13]. Abrupt withdrawal of agomelatine has not been associated with discontinua ...
... Agomelatine is an antidepressant agent with selective agonist action at melatonin receptors and selective antagonist action at serotonin 5HT-2C receptors. It does not affect uptake of serotonin, noradrenaline or dopamine [13]. Abrupt withdrawal of agomelatine has not been associated with discontinua ...
ROCEPHIN® (ceftriaxone sodium) FOR INJECTION Rx only To
... intervals, a half-life of 25 hours was calculated. Ceftriaxone is highly bound to plasma proteins. The extent of binding to proteins in the middle ear fluid is unknown. Interaction with Calcium: Two in vitro studies, one using adult plasma and the other neonatal plasma from umbilical cord blood have ...
... intervals, a half-life of 25 hours was calculated. Ceftriaxone is highly bound to plasma proteins. The extent of binding to proteins in the middle ear fluid is unknown. Interaction with Calcium: Two in vitro studies, one using adult plasma and the other neonatal plasma from umbilical cord blood have ...
Switching between tricyclic, SSRI and related antidepressants
... Agomelatine is an antidepressant agent with selective agonist action at melatonin receptors and selective antagonist action at serotonin 5HT-2C receptors. It does not affect uptake of serotonin, noradrenaline or dopamine [13]. Abrupt withdrawal of agomelatine has not been associated with discontinua ...
... Agomelatine is an antidepressant agent with selective agonist action at melatonin receptors and selective antagonist action at serotonin 5HT-2C receptors. It does not affect uptake of serotonin, noradrenaline or dopamine [13]. Abrupt withdrawal of agomelatine has not been associated with discontinua ...
Treatment issues for psychiatric comorbidities of epilepsy
... natremia, sexual dysfunction, bleeding and extrapyramidal symptoms [24] . It is, therefore, important to monitor patients for clinical signs of hyponatremia and test electrolytes when SSRIs are prescribed in combination with oxcarbazepine or carbamazepine. Sexual dysfunction is due to 5‑HT2 receptor ...
... natremia, sexual dysfunction, bleeding and extrapyramidal symptoms [24] . It is, therefore, important to monitor patients for clinical signs of hyponatremia and test electrolytes when SSRIs are prescribed in combination with oxcarbazepine or carbamazepine. Sexual dysfunction is due to 5‑HT2 receptor ...
used
... b. When BDZs bind to their receptor on the GABAA complex, they enhance the effect of GABA by increasing the number of times the chloride channel opens. However, in the absence of GABA, BDZs have no effect. Barbiturates also increase the affinity of the GABAA receptor complex for GABA, but they incre ...
... b. When BDZs bind to their receptor on the GABAA complex, they enhance the effect of GABA by increasing the number of times the chloride channel opens. However, in the absence of GABA, BDZs have no effect. Barbiturates also increase the affinity of the GABAA receptor complex for GABA, but they incre ...
Disease Progression Model
... indication of a disease modifying effect. Before bronchodilation, the annual rates of decline were the same in the tiotropium group and the placebo group: 30±1 ml per year. After bronchodilation, the annual rate of decline was 40±1 ml per year in the tiotropium group, as compared with 42±1 ml per ye ...
... indication of a disease modifying effect. Before bronchodilation, the annual rates of decline were the same in the tiotropium group and the placebo group: 30±1 ml per year. After bronchodilation, the annual rate of decline was 40±1 ml per year in the tiotropium group, as compared with 42±1 ml per ye ...
Herb-Drug Interactions: What Clinicians Need to Know.
... The majority of data on herb-drug interactions are theoretical and based on case reports, in vitro assays, animal studies, and/or speculation.6 Case reports are frequently cited as unequivocal evidence of dangerous interactions, despite the fact that “published case reports are often incomplete” and ...
... The majority of data on herb-drug interactions are theoretical and based on case reports, in vitro assays, animal studies, and/or speculation.6 Case reports are frequently cited as unequivocal evidence of dangerous interactions, despite the fact that “published case reports are often incomplete” and ...
Drug Information Shellfish Allergy
... combined with pharmaceutical grade ingredients and subjected to rigorous testing for safety and tolerability. This helps make sure that the calcium carbonate is in a form that is readily ingested, disintegrated and metabolized by the human body. Since the source of calcium carbonate for Os-Cal Calci ...
... combined with pharmaceutical grade ingredients and subjected to rigorous testing for safety and tolerability. This helps make sure that the calcium carbonate is in a form that is readily ingested, disintegrated and metabolized by the human body. Since the source of calcium carbonate for Os-Cal Calci ...
Childhood-onset Eye Disorders - Sight Loss and Vision Priority
... Is it safe to treat adults with untreated amblyopia using perceptual learning techniques? Is it possible to determine which eyes are likely to benefit from occlusion therapy administered in patients with different types of amblyopia? ...
... Is it safe to treat adults with untreated amblyopia using perceptual learning techniques? Is it possible to determine which eyes are likely to benefit from occlusion therapy administered in patients with different types of amblyopia? ...
Recreational Drugs - Immunodeficiency Clinic
... predisposing to resistance and decreasing efficacy. ...
... predisposing to resistance and decreasing efficacy. ...
Product Monograph Template - Standard
... hallucination or atypical psychosis have been reported. Pediatrics (< 4 years of age): The safety and efficacy in children below the age of 4 years has not been established. Geriatrics: As with other beta2-agonists, special caution should be observed when using VENTOLIN® HFA in elderly patients who ...
... hallucination or atypical psychosis have been reported. Pediatrics (< 4 years of age): The safety and efficacy in children below the age of 4 years has not been established. Geriatrics: As with other beta2-agonists, special caution should be observed when using VENTOLIN® HFA in elderly patients who ...
Product Monograph
... Amphetamines have a potential for abuse, misuse, dependence, or diversion for non-therapeutic uses that physicians should consider when prescribing this product (see Precautions, Dependence Liability.) The misuse of amphetamines may cause serious cardiovascular adverse events and sudden death. Pre-e ...
... Amphetamines have a potential for abuse, misuse, dependence, or diversion for non-therapeutic uses that physicians should consider when prescribing this product (see Precautions, Dependence Liability.) The misuse of amphetamines may cause serious cardiovascular adverse events and sudden death. Pre-e ...
Lortab® (hydrocodone bitartrate and acetaminophen tablets
... shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia. The rate of development of tolerance varies among patients. Physicians should be aware that abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical ...
... shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia. The rate of development of tolerance varies among patients. Physicians should be aware that abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical ...
Cannabinoids in bipolar affective disorder: a review and
... 2-week prescription for 30 mg daily in 1 week. A recent manic episode was associated with a severe behaviour disturbance involving a further possible detention order. The psychiatrist was called for a home visit, which he made some hours later. To his surprise, he found the patient calm, almost sere ...
... 2-week prescription for 30 mg daily in 1 week. A recent manic episode was associated with a severe behaviour disturbance involving a further possible detention order. The psychiatrist was called for a home visit, which he made some hours later. To his surprise, he found the patient calm, almost sere ...
Enhancement of Excessive Lever-Pressing After Post
... interval. Each rat was trained until it completed 30 trials in which it inserted its head into the food magazine during stimulus presentation, or until a total of 40 trials was reached. Stage 2: Lever-press training. Rats were trained to lever-press in a discrete-trial procedure. The start of each t ...
... interval. Each rat was trained until it completed 30 trials in which it inserted its head into the food magazine during stimulus presentation, or until a total of 40 trials was reached. Stage 2: Lever-press training. Rats were trained to lever-press in a discrete-trial procedure. The start of each t ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.